Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B I Rini

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
ESMO Open|October 22, 2023
Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101Y Tomita, R J Motzer, T K Choueiri, et al.
The Pharmacogenomics Journal|January 27, 2016
Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinomaM H Diekstra, A Belaustegui, J J Swen, et al.
ESMO Open|January 18, 2021
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among expertsS Aeppli, M Schmaus, T Eisen, et al.
ESMO Open|April 27, 2023
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinomaJ B A G Haanen, J Larkin, T K Choueiri, et al.
British Journal of Cancer|January 18, 2014
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinomaT E Hutson, R M Bukowski, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2011
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapyD Y Heng, M J Mackenzie, U N Vaishampayan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinomaB I Rini, L Albiges, X Tang, et al.
British Journal of Cancer|May 15, 2014
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trialB Escudier, M D Michaelson, R J Motzer, et al.
ESMO Open|September 3, 2021
Erratum to 'Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial': [ESMO Open Volume 6, Issue 3, June 2021, 100101]T K Choueiri, J Larkin, S Pal, et al.
ESMO Open|April 26, 2021
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trialT K Choueiri, J Larkin, S Pal, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
ESMO Open|October 22, 2023
Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101Y Tomita, R J Motzer, T K Choueiri, et al.
The Pharmacogenomics Journal|January 27, 2016
Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinomaM H Diekstra, A Belaustegui, J J Swen, et al.
ESMO Open|January 18, 2021
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among expertsS Aeppli, M Schmaus, T Eisen, et al.
ESMO Open|April 27, 2023
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinomaJ B A G Haanen, J Larkin, T K Choueiri, et al.
British Journal of Cancer|January 18, 2014
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinomaT E Hutson, R M Bukowski, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2011
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapyD Y Heng, M J Mackenzie, U N Vaishampayan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinomaB I Rini, L Albiges, X Tang, et al.
British Journal of Cancer|May 15, 2014
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trialB Escudier, M D Michaelson, R J Motzer, et al.
ESMO Open|September 3, 2021
Erratum to 'Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial': [ESMO Open Volume 6, Issue 3, June 2021, 100101]T K Choueiri, J Larkin, S Pal, et al.
ESMO Open|April 26, 2021
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trialT K Choueiri, J Larkin, S Pal, et al.
Pageof 4